Kolmar BNH’s HemoHIM gets dual recognition for fatigue improvement, immune enhancement
Kolmar BNH confirmed dual functionality of HemoHIM for immune enhancement and fatigue improvement.
-
Kolmar BNH confirmed dual functionality of HemoHIM for immune enhancement and fatigue improvement
SEOUL--(Korea Newswire)--Kolmar BNH, a Korean health supplement original development manufacturing (ODM), said the Ministry of Food and Drug Safety has recognized both fatigue improvement and immune enhancement capabilities for HemoHIM, a health-functional food developed by the company.
Introduced in 2006, HemoHIM was developed by Kolmar BNH using Korean natural materials like Angelica gigas Nakai, Cnidium officinale Makino, and Paeonia lactiflora Pallas.
It is the first health-functional food in Korea to be individually approved for immune function improvement.
Atomy, a Korean partner company, markets the product in Korea, while also exporting it to over 20 countries, including the U.S. and China.
The company has been conducting research since 2017 after it saw the possibility of HemoHIM’s efficacy in fatigue improvement.
Clinical trials and non-clinical trials revealed significant improvements in the Fatigue Severity Scale (FSS) and Multidimensional Fatigue Inventory (MFI) when healthy adult men and women aged between 30 and 60 consumed the HemoHIM.
The clinical trial results were published in Phytomedicine Plus, an academic journal focusing on natural medical products, with the company registering related patents in Korea and Russia.
Kolmar BNH plans to continue in-depth research on the HemoHIM to secure additional global intellectual property rights.
Kolmar BNH said that HemoHIM is unique in securing both immune function enhancement and fatigue improvement functionalities among individually approved ingredients. The company added that it plans to accelerate its approach to the global market with this differentiated ingredient.
Website: https://shop.atomy.com/
Contact
ATOMY
Park Kyung Tae Manager
070-5121-0281
This is a news release distributed by Korea Newswire on behalf of this company.